Schering Aktiengesellschaft

University of Texas System

Other

Eastern Virginia Medical School

Shering Ag

Krzysztof Chwalisz

Walter Elger

Robert E Garfield

Radoslaw Bukowski

Sybille Beier

Eckhard Ottow

Chandra Yallampalli

Stefan Scholz

Wolfgang Schwede

Arwed Cleve

Guenter Neef

Gunter Neef

Martin Schneider

Marianne Fahnrich

Syed Hamiduddin Hasan

Beate Kosub

Helmut Hofmeister

Karl-Heinrich Fritzemeier

Gary D Hodgen

James R Bull

Horst Michna

Marianne Faehnrich

Gordon Oliver Potts

Robert A Garfield

Chandra Yallamp'al Li

Chandra Yallampal Li

Angelika Esch

Menses regulation and, when desired, contraception is achieved at low doses of estrogen and progestin, which otherwise would create episodes of breakthrough bleeding and/or withdrawal amenorrhea, by periodically inducing menses with an antiprogestin.

Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception

Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI-mimetic, a thromboxane (TXA) inhibitor, a compound possessing TXA-agonistic and TXA-inhibiting properties, a compound possessing TXA-antagonistic and PGI-memetic activities, and a TXAantagonist.

Treatment of preeclampsia, toxemia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor

Muscle cells and nerves of the uterus and cervix are treated with electrical pulses having selectives parameters in order to stimulate or inhibit contraction thereof. Either a needle or probe is provided having stimulation electrodes thereon from which the treatment pulses emanate. In a further embodiment, patients are simultaneously treated with pharmacological agents in conjuction with the electrical treatment.

Methods of and apparatus for activating the muscle cells or nerves of the uterus or cervix

A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount of

Implantation rates after in vitro fertilization, treatment of

Muscle cells and nerves of the uterus and cervix are treated with electrical pulses having selective parameters in order to stimulate or inhibit contraction thereof. Either a needle or probe is provided having stimulation electrodes thereon from which the treatment pulses emanate. In a further embodiment, patients are simultaneously treated with pharmacological agents in conjunction with the electrical treatment.

Methods for activating the muscle cells or nerves of the uterus or cervix

Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -memetic activities, and a TXA.sub.2 antagonist.

Treatment of preeclampsia and preterm labor with combination of

Dysmenorrhea, disfunctional uterine bleeding, preterm labor and postpartum labor in female mammals are treated by inhibiting uterine contractility by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in combination with one or more of a prostaglandin inhibitor, a prostacyclin-mimetic, a progestin, an oxytocin antagonist or a .beta.-agonist in an amount effective to ameliorate the symptoms thereof; and inadequate menses treated and induction of abortion or stimulation of labor in a pregnant female is achieved by uterine contractility stimulation by administering thereto a nitric oxide inhibitor, either alone or optionally in a combination of progesterone antagonist, an oxytocin or oxytocin analogue antagonist or a prostaglandin.

Treatment of uterine contractility disorders with a nitric oxide

The symptoms of the climacterium are ameliorated by the administration to an afflicted individual one or both of a nitric oxide substrate and/or nitric acid donor, alone or optionally in combination with a progestin or, in the case of a non-pregnant female, either a progestin or an estrogen or both.

Treatment of climacteric disorders with nitric oxide synthase substrates

Dysmenorrhea, disfunctional uterine bleeding, preterm labor and postpartum labor in female mammals are treated by inhibiting uterine contractility by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in combination with one or more of a prostaglandin inhibitor, a prostacyclin-mimetic, a progestin, an oxytocin antagonist or a .beta.-agonist in an amount effective to ameliorate the symptoms thereof; and inadequate menses treated and induction of abortion or stimulation of labor in a pregnant female is achieved by uterine contractility stimulation by administering thereto a nitric oxide inhibitor, either alone or optionally in a combination of progesterone antagonist, an oxytocin or-oxytocin analogue antagonist or a prostaglandin.

6,7-modified 11.beta.-aryl-4-oestrenes

A pharmaceutical agent contains a progesterone synthesis inhibitor (ProI) of the trilostane or epostane type and an antigestagen (AG). It can be used for inducing delivery at term in humans and animals, for terminating normal or pathological pregnancies therein or for treatment of hormone-dependent tumors, endometriosis or dysmenorrhea.

Combined use of an antigestagen and a progesterone synthesis inhibitor

Antigestagens inhibit prostaglandin synthesis by the uterus and thus can be used to treat symptoms of dysmennhorea.

Antigestagens for the inhibition of uterine synthesis of prostaglandin

The existence of gap junctions between cells is detected by stimulating the cells with electrical pulses having selective parameters and then detecting propagated signals emitted by the cells. A needle is provided having stimulation electrodes thereon from which the stimulating pulses emanate and an array of recording electrodes for detecting the pulses. In an alternative embodiment, an array of piezoelectric electrodes is distributed within the array of recording electrodes. The signals detected by the recording electrodes and piezoelectric electrodes are monitored by a recording device and stored within a computer.

Growing community of inventors

Berlin, Germany

Krzysztof Chwalisz